Curasight (CURAS) Q2 2025 earnings summary

Executive summary

• Advanced clinical development of theranostic platforms uTRACE and uTREAT, focusing on prostate cancer and glioblastoma.

• Completed a successful fundraise: DKK 47 million in new share capital and DKK 18 million in loans, strengthening the financial base.

• EMA approved clinical trial application for phase 1 uTREAT trial in glioblastoma; first patient dosing expected in H2 2025.

• Expanded phase 2 uTRACE trial in prostate cancer, with recruitment expected to complete in H1 2026.

Financial highlights

• Q2 2025 gross loss: KDKK -17,700 (Q2 2024: KDKK -9,001); H1 2025 gross loss: KDKK -22,399 (H1 2024: KDKK -16,386).

• Q2 2025 operating loss: KDKK -19,011 (Q2 2024: KDKK -10,969); H1 2025 operating loss: KDKK -25,220 (H1 2024: KDKK -20,345).

• Q2 2025 loss for the period: KDKK -19,204 (Q2 2024: KDKK -10,737); H1 2025 loss: KDKK -24,408 (H1 2024: KDKK -18,729).

• Total assets as of June 30, 2025: KDKK 44,783 (June 30, 2024: KDKK 28,847); cash at hand: KDKK 29,449 (KDKK 8,384).

• Equity ratio improved to 67.6% (43.9% in 2024); EPS for H1 2025: DKK -0.54 (H1 2024: DKK -0.94).

Outlook and guidance

• Preliminary efficacy data from glioblastoma phase 1 trial expected by end of Q4 2025.

• Phase 2 uTRACE prostate cancer trial recruitment to complete in H1 2026, with topline results anticipated thereafter.

• Plans to initiate a phase II basket trial in 2026, covering multiple cancer indications.